Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer
10.13422/j.cnki.syfjx.202202021
- VernacularTitle:防风通圣散治疗原发性肝癌和结直肠癌术后肝转移介入栓塞后综合征的临床疗效观察
- Author:
Lin YANG
1
;
Fangling LIU
2
;
Yan WU
2
;
Guowang YANG
1
;
Qi FU
1
;
Qingsheng FAN
1
;
Qing ZHANG
1
;
Xiaomin WANG
1
Author Information
1. Beijing Hospital of Traditional Chinese Medicine（TCM）， Capital Medical University， Beijing 100010， China
2. Luan Ping Hospital of TCM， Chengde 062850， China
- Publication Type:Journal Article
- Keywords:
Fangfeng Tongshengsan;
post-chemoembolization syndrome;
transcatheter hepatic arterial chemoembolization;
primary liver cancer;
postoperative liver metastases of colorectal cancer
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(15):103-109
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the effect of the Fangfeng Tongshengsan on post-chemoembolization syndrome with primary liver cancer or postoperative liver metastases of colorectal cancer. MethodSeventy-two patients suffered from post-chemoembolization syndrome after transcatheter hepatic arterial chemoembolization were randomly divided into 2 groups， including a Fangfeng Tongshengsan group and a control group， with 36 patients in each group. The patients in Fangfeng Tongshengsan group orally took the decoction for consecutive 7 d. The patients in the control group were physically cooled down with alcohol rub bath and ice pack for consecutive 7 d. Furthermore， the difference of fever， Karnofsky performance status （KPS）， pain in the liver region， nausea vomiting， constipation， and liver function between these two groups were observed. ResultCompared with the control group， Fangfeng Tongshengsan significantly relieved fever， reduced the body temperature （P<0.05）， and shortened the duration of fever （P<0.05）， indicating that Fangfeng Tongshengsan remarkably improved the KPS （P<0.05）. Meanwhile， Fangfeng Tongshengsan obviously alleviated nausea， vomiting， and constipation status and shortened the duration time compared with the control group （P<0.05）. In addition， the parameters of liver function including alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， γ-glutamyl transpeptidase （GGT）， and total bilirubin （TBIL） were significantly decreased in the Fangfeng Tongshengsan group （P<0.05）， which indicated that Fangfeng Tongshengsan alleviated liver dysfunction of patients with post-chemoembolization syndrome. ConclusionFangfeng Tongshengsan can be used to treat post-chemoembolization syndrome with primary liver cancer and postoperative liver metastases of colorectal cancer.
